Here is a plain-language interpretation of this 3-page 18F-FDG Whole Body PET-CT second opinion report from Sir H.N. Reliance Foundation Hospital, dated 12 May 2026.
Patient Summary
Patient: Kapil Agarwal, 51-year-old male
Background: Carcinoma of the left buccal mucosa (squamous cell carcinoma, confirmed on biopsy). He previously underwent:
- Left composite resection + marginal mandibulectomy + left sentinel node biopsy with reconstruction (January 2025)
- Radiation therapy (April 2025)
- A prior PET-CT (January 2026) showed a new lesion along the right mandibular ramus and a spiculated lung opacity - confirmed right cheek lesion SCC on biopsy
- Has been on chemotherapy since then
Purpose of this scan: To evaluate response to chemotherapy.
Region-by-Region Findings
Brain
- Normal. No abnormal metabolic activity or lesions.
Head & Neck (Left Side - Operative Site)
- Good news on the left: The surgical flap reconstruction looks stable. No abnormal FDG uptake or enhancing lesions at the operative bed - no signs of local recurrence on the treated side.
- Left neck nodes: No significantly enlarged or FDG-avid nodes (no active nodal disease on the left).
Head & Neck (Right Side - Active Disease)
- There is a persistent soft tissue lesion along the right mandibular ramus, infiltrating the upper right masseter muscle.
- Size reduced: From 3.6 x 2.6 x 3.1 cm → now 3.2 x 2.3 x 2.6 cm
- SUVmax reduced: From 8.2 → now 7.1 (SUVmax reflects metabolic activity; lower = less active)
- The lesion still erodes the right zygomatic bone cranially, but no significant destruction of the mandibular ramus itself.
- It has effaced fat planes near the right parotid gland and infiltrates the subcutaneous space, but the overlying skin appears uninvolved.
- Small right neck level IB, II, and tiny level III nodes show low-grade FDG uptake - considered likely reactive (not malignant) and are stable.
Thorax (Lungs)
- A persistent spiculated opacity (irregular lung mass) in the right lung perihilar region, abutting the right pulmonary artery (middle/lower lobe branches).
- Size reduced: From 2.8 x 2.4 x 2.5 cm → now 2.3 x 1.6 x 2.5 cm
- SUVmax: 6.14 (previously 6.4) - marginally reduced metabolic activity
- Causing compression of right middle lobe bronchi with some distal collapse (atelectasis).
- No pleural effusion. No other lung lesions. No enlarged mediastinal or axillary nodes.
Abdomen & Pelvis
- Liver, spleen, gallbladder, pancreas, adrenals, left kidney: All normal.
- Tiny calcium deposit in the right kidney (incidental, likely benign).
- Prostate is mildly enlarged but shows no suspicious FDG uptake.
- No abnormal nodes in the abdomen or pelvis.
Musculoskeletal / Bones
- No FDG-avid lytic or sclerotic bone metastases anywhere in the body.
Overall Conclusion (Radiologist's Remarks)
The report concludes:
"Overall scan findings are suggestive of partial response to treatment."
In plain terms, this means:
- The right mandibular/masseter lesion has shrunk slightly and become slightly less metabolically active, but it is still present and still active (SUVmax 7.1 is significantly elevated).
- The right lung lesion has also partially reduced in size but remains active.
- The left-side surgical site is clean - no recurrence there.
- No new metastatic sites have appeared anywhere in the body.
What "Partial Response" Means Clinically
In oncology response criteria (e.g., RECIST or PERCIST):
- Complete response = no detectable disease
- Partial response = measurable reduction in tumor size/activity (typically >30% reduction in size), but disease is still present
- Stable disease = no significant change
- Progressive disease = tumor growth or new lesions
This patient falls into partial response - chemotherapy is working to some degree, but the disease has not been eliminated. The treating oncologist will need to decide whether to continue the same regimen, intensify it, switch to a different regimen, or consider other interventions (such as surgery or radiation to the residual sites).
Important note: This interpretation is for informational purposes only. Treatment decisions should be made by the patient's oncology team, who have the full clinical context.